Aurinia Pharmaceuticals (AUPH) News Today $8.24 +0.11 (+1.35%) (As of 11/20/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period Aurinia Pharmaceuticals Celebrates New Lupus Nephritis GuidelinesNovember 19 at 12:30 AM | markets.businessinsider.comAurinia Commends 2024 Updated ACR Guidelines for Screening, Treatment, and Management of Lupus NephritisNovember 18 at 6:04 PM | financialpost.comAurinia Commends 2024 Updated ACR Guidelines for Screening, Treatment, and Management of Lupus NephritisNovember 18 at 5:53 PM | businesswire.comGSA Capital Partners LLP Sells 102,373 Shares of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH)GSA Capital Partners LLP cut its position in shares of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH - Free Report) (TSE:AUP) by 44.9% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 125,645 shares of the bioteNovember 17, 2024 | marketbeat.comAurinia Highlights Lupus Nephritis Breakthroughs at ACR 2024November 16, 2024 | markets.businessinsider.comAurinia Presents New Data Underscoring Critical Importance of Earlier Lupus Nephritis Detection and Intervention and Value of LUPKYNIS® in Managing LN at American College of Rheumatology Convergence 2024November 15, 2024 | businesswire.comAurinia Pharmaceuticals Engages at London ConferenceNovember 15, 2024 | markets.businessinsider.comAurinia to Participate in Jefferies London Healthcare ConferenceNovember 14, 2024 | businesswire.comInsider Selling: Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Director Sells 4,557 Shares of StockNovember 13, 2024 | insidertrades.comPositive Outlook on Aurinia Pharmaceuticals Amid Strong Financial Performance and Strategic Cost ManagementNovember 11, 2024 | markets.businessinsider.comResearch Analysts Offer Predictions for AUPH Q1 EarningsAurinia Pharmaceuticals Inc. (NASDAQ:AUPH - Free Report) (TSE:AUP) - Investment analysts at Leerink Partnrs lifted their Q1 2025 earnings per share estimates for shares of Aurinia Pharmaceuticals in a note issued to investors on Thursday, November 7th. Leerink Partnrs analyst J. Schwartz now antiNovember 11, 2024 | marketbeat.comAurinia Pharmaceuticals (NASDAQ:AUPH) Upgraded at StockNews.comStockNews.com raised Aurinia Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research note on Friday.November 8, 2024 | marketbeat.comAurinia Pharmaceuticals: A Potential Buyout Looms On The HorizonNovember 8, 2024 | seekingalpha.comAurinia Pharmaceuticals Inc (AUPH) Q3 2024 Earnings Call Highlights: Strong Revenue Growth Amid ...November 8, 2024 | finance.yahoo.comAurinia Pharmaceuticals (NASDAQ:AUPH) Stock Price Up 11% - Should You Buy?Aurinia Pharmaceuticals (NASDAQ:AUPH) Stock Price Up 11% - Should You Buy?November 7, 2024 | marketbeat.comAurinia Pharmaceuticals, Inc. (AUPH) Q3 2024 Earnings Call TranscriptNovember 7, 2024 | seekingalpha.comShareholders in Aurinia Pharmaceuticals (NASDAQ:AUPH) are in the red if they invested three years agoNovember 2, 2024 | finance.yahoo.comAurinia Pharmaceuticals (AUPH) Scheduled to Post Earnings on ThursdayAurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) will be releasing earnings before the market opens on Thursday, November 7, Zacks reports.October 31, 2024 | marketbeat.comAurinia Pharmaceuticals to Release Third Quarter Financial and Operational Results on November 7, 2024October 30, 2024 | businesswire.comAurinia Pharmaceuticals (NASDAQ:AUPH) Stock, Short Interest ReportOctober 19, 2024 | benzinga.comAurinia Pharmaceuticals (NASDAQ:AUPH) Stock Quotes, Forecast and News SummaryOctober 19, 2024 | benzinga.comAQR Capital Management LLC Takes Position in Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH)AQR Capital Management LLC purchased a new position in shares of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH - Free Report) (TSE:AUP) during the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 202,241 shares of the biotechnologOctober 12, 2024 | marketbeat.comSG Americas Securities LLC Grows Stock Position in Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH)SG Americas Securities LLC grew its position in Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH - Free Report) (TSE:AUP) by 4,307.9% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 547,727October 7, 2024 | marketbeat.comAlgert Global LLC Acquires 100,104 Shares of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH)Algert Global LLC lifted its holdings in Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH - Free Report) (TSE:AUP) by 106.8% in the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 193,804 shares of the biotechnology compaOctober 5, 2024 | marketbeat.comStonepine Capital Management LLC Takes $1.71 Million Position in Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH)Stonepine Capital Management LLC bought a new position in shares of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH - Free Report) (TSE:AUP) during the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 300,000 shares of the biotechOctober 1, 2024 | marketbeat.comShort Interest in Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Declines By 13.0%Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH - Get Free Report) (TSE:AUP) was the target of a significant drop in short interest in September. As of September 15th, there was short interest totalling 7,580,000 shares, a drop of 13.0% from the August 31st total of 8,710,000 shares. Based on an average daily trading volume, of 1,420,000 shares, the days-to-cover ratio is presently 5.3 days.September 28, 2024 | marketbeat.comAurinia Pharmaceuticals: Strategic Growth and Buy Rating Amidst Japan Market Expansion and M&A PotentialSeptember 27, 2024 | markets.businessinsider.comAurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Could Be Less Than A Year Away From ProfitabilitySeptember 27, 2024 | finance.yahoo.comAurinia Announces Japan Approval of LUPKYNIS ® (Voclosporin) to Treat Lupus NephritisSeptember 26, 2024 | businesswire.comArmistice Capital LLC Lowers Holdings in Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH)Armistice Capital LLC reduced its stake in shares of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH - Free Report) (TSE:AUP) by 9.2% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 11,136,000 shares of the bSeptember 26, 2024 | marketbeat.comAurinia Pharma Gets Approval in Japan for Lupus TreatmentSeptember 24, 2024 | marketwatch.comAurinia Announces Japan Approval of LUPKYNIS® (Voclosporin) to Treat Lupus NephritisSeptember 24, 2024 | stockhouse.comAurinia Announces Approval Of LUPKYNIS In Japan - Quick FactsSeptember 24, 2024 | markets.businessinsider.comAurinia Pharmaceuticals: This Recovery Can ContinueSeptember 18, 2024 | seekingalpha.comAurinia Pharmaceuticals (NASDAQ:AUPH) Trading 4% Higher Aurinia Pharmaceuticals (NASDAQ:AUPH) Trading Up 4%September 16, 2024 | marketbeat.comAurinia Pharmaceuticals' (AUPH) "Overweight" Rating Reiterated at Cantor FitzgeraldCantor Fitzgerald reiterated an "overweight" rating and set a $10.00 price target on shares of Aurinia Pharmaceuticals in a research report on Monday.September 16, 2024 | marketbeat.comBank of New York Mellon Corp Raises Stock Position in Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH)Bank of New York Mellon Corp raised its stake in Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH - Free Report) (TSE:AUP) by 18.8% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 488,721 shares ofSeptember 16, 2024 | marketbeat.comAurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Stock Holdings Reduced by Jupiter Asset Management Ltd.Jupiter Asset Management Ltd. cut its position in shares of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH - Free Report) (TSE:AUP) by 35.8% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 158,497 sharesSeptember 14, 2024 | marketbeat.comAurinia Pharmaceuticals (NASDAQ:AUPH) Shares Gap Up to $6.58Aurinia Pharmaceuticals (NASDAQ:AUPH) Shares Gap Up to $6.58September 13, 2024 | marketbeat.comAurinia Announces Board RestructuringSeptember 12, 2024 | finance.yahoo.comAurinia Pharmaceuticals (NASDAQ:AUPH) Stock Price Down 3.2%Aurinia Pharmaceuticals (NASDAQ:AUPH) Trading Down 3.2%September 9, 2024 | marketbeat.comCantor Fitzgerald Reaffirms "Overweight" Rating for Aurinia Pharmaceuticals (NASDAQ:AUPH)Cantor Fitzgerald reaffirmed an "overweight" rating and set a $10.00 target price on shares of Aurinia Pharmaceuticals in a research report on Monday.September 9, 2024 | marketbeat.comAurinia Pharmaceuticals (NASDAQ:AUPH) Shares Up 3.3%Aurinia Pharmaceuticals (NASDAQ:AUPH) Stock Price Up 3.3%September 6, 2024 | marketbeat.comAurinia Pharmaceuticals (NASDAQ:AUPH) Rating Reiterated by HC WainwrightHC Wainwright reaffirmed a "buy" rating and set a $13.00 price objective on shares of Aurinia Pharmaceuticals in a research report on Friday.September 6, 2024 | marketbeat.comAurinia Pharmaceuticals Target of Unusually High Options Trading (NASDAQ:AUPH)Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH - Get Free Report) (TSE:AUP) was the target of unusually large options trading on Thursday. Stock traders bought 4,319 call options on the stock. This is an increase of 107% compared to the typical daily volume of 2,091 call options.September 5, 2024 | marketbeat.comAurinia Announces First Participant Dosed in AUR200 Single Ascending Dose TrialSeptember 5, 2024 | finance.yahoo.comShort Interest in Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Declines By 13.8%Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH - Get Free Report) (TSE:AUP) was the target of a significant decrease in short interest during the month of August. As of August 15th, there was short interest totalling 8,480,000 shares, a decrease of 13.8% from the July 31st total of 9,840,000 shares. Based on an average trading volume of 1,310,000 shares, the days-to-cover ratio is presently 6.5 days.August 31, 2024 | marketbeat.comAurinia to Participate in H.C. Wainwright 26th Annual Global Investment ConferenceAugust 28, 2024 | finance.yahoo.comAurinia Pharmaceuticals (NASDAQ:AUPH) Trading 2.4% Higher Aurinia Pharmaceuticals (NASDAQ:AUPH) Trading 2.4% HigherAugust 28, 2024 | marketbeat.comAurinia Pharmaceuticals (NASDAQ:AUPH) Stock Passes Above 50 Day Moving Average of $5.73Aurinia Pharmaceuticals (NASDAQ:AUPH) Stock Price Passes Above 50 Day Moving Average of $5.73August 28, 2024 | marketbeat.com Get Aurinia Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for AUPH and its competitors with MarketBeat's FREE daily newsletter. Email Address [625,000% Gain] – Are You Ready for the Next Altcoin Boom? (Ad)All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you know anything about crypto, you know that altcoin seasons are where some of the biggest gains happen. Register for the FREE Workshop Now & get $10 in Bitcoin AUPH Media Mentions By Week AUPH Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. AUPH News Sentiment▼0.860.45▲Average Medical News Sentiment AUPH News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. AUPH Articles This Week▼83▲AUPH Articles Average Week Get Aurinia Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for AUPH and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies RCKT News IGMS News YMAB News CYRX News AMRN News AXSM News ALKS News BBIO News RARE News PBH News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:AUPH) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredElon knows the truth, which is why they want him silencedElon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to h...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aurinia Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aurinia Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free AUPH Stock Alerts